Edition:
India

Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

91.06USD
20 Jul 2018
Change (% chg)

-- (--)
Prev Close
$91.06
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
142,097
52-wk High
$99.77
52-wk Low
$51.66

Select another date:

Fri, Jul 20 2018

Agios Pharmaceuticals leukemia drug gets U.S. approval

Agios Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration approved its treatment for a type of leukemia, the first targeted drug for patients with a specific genetic mutation.

UPDATE 1-Agios Pharmaceuticals leukemia drug gets U.S. approval

July 20 Agios Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration approved its treatment for a type of leukemia, the first targeted drug for patients with a specific genetic mutation.

FDA approves Agios Pharmaceuticals leukemia drug

July 20 Agios Pharmaceuticals Inc said on Friday its oral drug to treat a type of leukemia was approved by the U.S. health regulator.

BRIEF-Agios Qtrly Loss Per Share $1.63

* AGIOS PROVIDES BUSINESS UPDATE ON DISCOVERY RESEARCH STRATEGY AND PIPELINE, PROGRESS ON CLINICAL PROGRAMS, COMMERCIAL LAUNCH PREPARATIONS AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AT INVESTOR DAY

BRIEF-Agios Says First Patient Dosed In Lymphoma Study

* AGIOS ANNOUNCES FIRST PATIENT DOSED WITH MAT2A INHIBITOR AG-270 IN PHASE 1 STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA WITH AN MTAP DELETION Source text for Eikon: Further company coverage:

BRIEF-Agios Reports Qtrly Loss Per Share $1.81

* AGIOS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Select another date: